Safety, efficacy and pharmacokinetics of palivizumab in off-label neonates, infants, and young children at risk for serious respiratory syncytial virus infection: a multicenter phase II clinical trialResearch in context

• Main Authors: Masaaki Mori (Author), Kanako Yoshizaki (Author), Shinichi Watabe (Author), Mika Ishige (Author), Akinari Hinoki (Author), Takuya Kondo (Author), Tomoaki Taguchi (Author), Hisaya Hasegawa (Author), Tomoko Hatata (Author), Naoyuki Tanuma (Author), Kosuke Kirino (Author), Akihiro Hirakawa (Author), Takuya Naruto (Author), Minoru Imai (Author), Ryuji Koike (Author), Kenichiro Hosoi (Author), Satoshi Kusuda (Author)
• Format: Book
• Published: Elsevier, 2023-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary: Background: Pediatric patients with certain rare diseases are at increased risk of severe respiratory syncytial virus (RSV) infection. However, the prophylactic use of anti-RSV antibody (palivizumab) in these patients is not indicated at present in Japan. Methods: This first-in-the-world mu...